Harrow (HROW) Return on Invested Capital (2017 - 2025)

Harrow (HROW) posted quarterly Return on Invested Capital of 0.0% for Q4 2024, down 99.69% quarter-over-quarter from 0.76% in Q4 2022.

Harrow (HROW) Return on Invested Capital (2017 - 2025) Analysis & Trends

Harrow's Return on Invested Capital history runs 3 years deep, the most recent figure standing at 0.0% for Q4 2024.

In Q4 2024, Return on Invested Capital changed N/A year-over-year to 0.0%; the TTM figure through Dec 2024 stood at 0.0% (changed N/A YoY), while the FY2021 annual figure was 0.76%, up 62.0% from the prior year.
Return on Invested Capital for Q4 2024 stood at 0.0%, down from 0.76% in the prior quarter.
The five-year high for Return on Invested Capital was 0.76% in Q4 2022, with the low at 0.25% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn	0.00%
3	Zoetis	31.78 Bn	30.11 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.71 Bn	22.91 Bn	5.10 Bn	0.00%
5	United Therapeutics	22.25 Bn	19.59 Bn	683.80 Mn	-
6	Viatris	18.72 Bn	17.83 Bn	1.46 Bn	0.00%
7	Neurocrine Biosciences	15.57 Bn	15.18 Bn	935.80 Mn	-
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn	0.03%
9	Dr Reddys Laboratories	10.14 Bn	9.97 Bn	-	-
10	Harrow	1.58 Bn	1.49 Bn	50.36 Mn	-

Download Data